PHAR — Pharming Group N.V.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1828316 ·
Last close
$12.06
Market Cap
$853.58M
52W High
$21.34
52W Low
$9.11
ADV30
14,397
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 117,557,000 | 102,193,000 | 27,591,000 | 22,428,000 | 496,637,000 | 189,560,000 | 205,398,000 |
| Jun 2026 | 90,213,000 | 75,668,000 | -111,000 | 1,638,000 | 467,984,000 | 158,281,000 | 197,494,000 |
| Mar 2026 | 72,447,000 | 65,803,000 | -5,288,000 | -5,213,000 | 489,365,000 | 52,379,000 | 220,405,000 |
| Dec 2025 | 106,500,000 | 85,400,000 | 2,000,000 | 5,300,000 | 499,963,000 | 145,305,000 | 222,861,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$35,372,000
Investing CF
$-85,167,000
Financing CF
$-11,025,000
CapEx
$-870,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-0.22
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-255,277,000
Inventory
$57,988,000
Receivables
$74,831,000
ST Investments
$0
EBIT TTM
$28,392,000
Pretax Income TTM
$34,330,000
Interest Exp TTM
$14,717,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$366,479,008
EBITDA
$32,879,000
Free Cash Flow
$37,686,124
Enterprise Value
$748,436,800
Total Cash
$158,280,992
Total Debt
$113,295,000
Shares Out
70,778,124
Trailing EPS
$0.14
Book Value
$3.82
ROE
3.6%
ROA
3.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 376,134,000 | 20,881,000 | 2,851,000 | 499,963,000 | 222,861,000 | 277,102,000 | 54,708,000 |
| Dec 2024 | 297,200,000 | -3,665,000 | -11,841,000 | 399,985,000 | 178,924,000 | 221,061,000 | -1,795,000 |
| Dec 2023 | 245,316,000 | -22,289,000 | -10,548,000 | 462,854,000 | 244,073,000 | 218,781,000 | -17,302,000 |
| Dec 2022 | 205,622,000 | 9,860,000 | 13,674,000 | 425,797,000 | 221,159,000 | 204,638,000 | 22,458,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.31
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CRVS | Corvus Pharmaceuticals, Inc. | $857.87M | $10.17 | — |
| CTY | CITY THERAPEUTICS, INC. | $846.44M | $17.50 | — |
| ORIC | Oric Pharmaceuticals, Inc. | $829.22M | $8.00 | — |
| AKTS | Aktis Oncology, Inc. | $879.52M | $16.31 | — |
| SNDX | Syndax Pharmaceuticals Inc | $828.26M | $9.20 | — |
News headlines (Yahoo Finance, 1h cache)
Pharming to participate in fireside chat at Jefferies Global Healthcare Conference in London
2026-11-11 07:00 · Yahoo
MHRA approves Pharming’s Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K.
2026-11-06 06:00 · Yahoo
Pharming: 3 Key Takeaways for Long-Term Investors
2026-11-04 22:20 · Yahoo
Pharming Group (ENXTAM:PHARM) Stock Faces A Q3 Earnings Valuation Gap
2026-10-28 05:17 · Yahoo
Pharming (PHAR) Q3 2026 Earnings Call Transcript
2026-10-27 17:30 · Yahoo
Pharming Group Q3 Earnings Call Highlights
2026-10-27 15:05 · Yahoo
Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in November
2026-10-27 06:00 · Yahoo
Pharming Group announces third quarter 2026 revenues above market expectations
2026-10-22 05:00 · Yahoo
Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026
2026-10-14 06:00 · Yahoo
Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026
2026-09-22 05:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.